News Releases

FARMINGDALE, N.Y., May 18, 2016 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, today announced that it will be participating in the Master Techniques in Spine Surgery Workshop on May 20, 2016 at the PARTI Center, Huashan Hospital, Fudan University and Chengdu International Exhibition and Convention Center (CIECC) located in Shanghai and Chengdu China respectively. 

Jointly planned by The North American Spine Society (NASS), the Chinese Association of Orthopedic Surgeons (CAOS), and the Chinese Medical Doctor Association, the program will initially provide for a live BoneScalpel technique demonstration by Professor Huajiang Chen, Vice Director, NO. 1 Spine Department, Changzheng Orthopedics Hospital of Second Military Medical University in Shanghai China.  Following Professor Chen's demonstration will be a hands-on cadaveric training for over 100 surgeon attendees at the PARTI Center in Shanghai China.  The demonstration will be broadcast live from the lab in Shanghai to the registrants of the Ninth Congress of the CAOS in Chengdu, China as well as to 30,000 online participants of the meeting.  According to Professor Chen, BoneScalpel "reduces the bleeding of bone, improves the efficiency, accuracy, and safety of spinal decompression. Especially useful for all types of osteotomies in severe spinal deformity correction surgeries."

Additionally, Professor Feng Li, Director of the Department of Orthopedic Surgery at Tongii Hospital in Wuhan China will lecture on the benefits of using BoneScalpel in advanced spine surgery.  "BoneScalpel represents a revolutionary change in spinal surgery," states Professor Li.

Scott Ludecker, Senior Vice President of Global Sales & Marketing, commented, "We are very excited to be one of a select group of companies participating in the Master Techniques in Spine Surgery workshop in Shanghai.  Misonix is committed to medical education and providing opportunities for surgeons to learn from their peers and we thank Professors Li and Chen for their support in these efforts."

"China has been an important marketplace for BoneScalpel in recent years and we look forward to exposing many more surgeons to the unique benefits of the BoneScalpel at this week's events.  Hands-on experience with the BoneScalpel in cadaveric labs, such as this one, are critical for surgeons to appreciate the important benefits of safety, less bleeding, better cutting and overall time savings that the BoneScalpel can bring to their surgical practices," added Michael A. McManus Jr., President and Chief Executive Officer of Misonix.

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Logo - http://photos.prnewswire.com/prnh/20160201/328020LOGO

SOURCE Misonix, Inc.